Pfizer exec makes an abrupt exit; Boehringer's Pradaxa beats warfarin in clotting;

@FierceBiotech: Biogen Idec preps for a big leap into the anti-TNF blockbuster biosimilars market. More | Follow @FierceBiotech

@JohnCFierce: "Amy Schulman and Pfizer have agreed to separate." What, no retirement? More | Follow @JohnCFierce

@DamianFierce:  Amgen keeps with the PCSK9 pack in its first Phase III results for evolocumab. News | Follow @DamianFierce

@EmilyMFierce: Researchers find a possible drug target for undruggable melanoma. Story | Follow @EmilyMFierce

> Boehringer Ingelheim's Pradaxa proved just as effective as warfarin in preventing blood clots, giving the company hope of winning a broader indication for the drug. News

> Pfizer's ($PFE) Amy Schulman is no longer with the company, a surprise departure revealed just weeks before she was meant to take the helm of the company's vaccines, oncology and consumer healthcare business. Article

> Researchers at Vanderbilt University have discovered some promising drug targets for hard-to-treat melanomas previously considered undruggable. More

Medical Device News

@FierceMedDev: TruTouch Technologies (biometric alcohol sensor) names Marathon's Bruce Berger CEO. Release | Follow @FierceMedDev

@MarkHFierce: In an interesting twist, ViewRay's new $30M round includes an investment from a Chinese distributor. Story | Follow @MarkHFierce

@MichaelGFierce: Alnylam begins PhII trial for amyloidosis RNAi treatment. Item from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: Boston Scientific recruits a veteran Silicon Valley investor amid its M&A push. More | Follow @GalenMoore

> Belgium's Cardio3 Biosciences gets $5.5M to advance heart catheter, stem cell treatment. Item

> SynCardia's $14M infusion will fuel formal testing of a smaller-sized heart implant. Story

Pharma News

@FiercePharma: Whoa: Amy Schulman is out, rather abruptly, at Pfizer. She was one of the three division chiefs chosen by CEO Ian Read earlier this year. | Follow @FiercePharma

@EricPFierce: Teva renegs on plans to build a new API plant in India. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Pfizer names Albert Bourla Group President; Vaccines, Oncology and Consumer Healthcare Business. Release | Follow @CarlyHFierce

> Almirall eyes growth in U.S., dermatology with $400M Aqua Pharma buyout. Story

> Traders bet Novartis CEO will bail out of its $14B Roche stake. More

> Amy Schulman, tapped to lead a new Pfizer division, makes an abrupt exit. News

> GlaxoSmithKline scraps doc payments, sales-rep quotas in global marketing revamp. Article

> Supreme Court won't take up ex-InterMune CEO's free-speech defense. Report

> Chinese whistleblower tags Shanghai Pharma with bribery allegations. Item

Pharma Manufacturing News

> China rounds up hundreds in crackdown against drug counterfeiters. More

> Novartis' OTC recall is tied to a contractor this time. Story

> Novartis to shed Alcon plant, 300 jobs next year. News

> What's a makeover cost these days? For AstraZeneca's distribution hub, $100M. Article

> Teva reneges on its proposal to build a $141M API plant in India. Report

> Wales fines companies £120,000 for worker accidents. Item

Biotech Research News

> Congressional budget deal would ease NIH sequester cuts. Story

> Report: Life science research needs standards to curb irreproducible studies. More

> CIRM awards $61M for cancer research. Item

> Researchers find possible drug targets for undruggable melanomas. News

> Blood vessel breakdown in the brain may be linked to Alzheimer's. Report

Glaxo compound slows Lou Gehrig's disease in animal models. Article

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.